September 24th 2021, 3:45pm
In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.
September 23rd 2021, 9:05pm
The reports suggest patients with rheumatoid arthritis (RA) could experience secondary neurological adverse events, though the side effect appears to be rare.
September 23rd 2021, 8:10pm
Intravenous belimumab had benefits, but also resulted in more health care utilization due to the nature of its administration.
September 23rd 2021, 6:00pm
A team of Australian researchers created and validated a model that may boost efficiency of type 1 diabetes (T1D) progression screening.
September 23rd 2021, 3:15pm
In a recent paper, researchers outlined the utility of minimal residual disease (MRD) among patient with acute lymphoblastic leukemia (ALL) and how its monitoring at specific timepoints has proven useful for stratifying patients and helping to ensure appropriate treatment decisionsMRD
September 23rd 2021, 1:30pm
Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.
September 22nd 2021, 9:50pm
Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.
September 22nd 2021, 6:30pm
Chronic graft-vs-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant in which the donated cells initiate an immune response and attack the transplant recipient’s organs.
September 21st 2021, 4:50pm
Among patients with COVID-19, chronic obstructive pulmonary disease and asthma were more prevalent than allergic rhinitis.
September 20th 2021, 2:23pm
New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.
